Table 1. Patients followed up for at least 42 months for survival evaluation.
Sample | Histologya | Tumor Stage | Age (years) | Treatmentb | Follow up (months) | Statusc |
R093 | ACC | IB1 | 57 | HT | 53 | Alive |
R446 | ACC | IB1 | 43 | HT | 59 | Alive |
R081 | ACC | IB1 | 41 | HT | 62 | Alive |
R094 | SCC | IB1 | 45 | HT | 62 | Alive |
R369 | SCC | IB1 | 50 | HT | 65 | Alive |
R057 | ACC | IB1 | 32 | HT | 93 | Alive |
R072 | SCC | IB1 | 61 | HT+TELE+BRACHY | 86 | Alive |
R411 | SCC | IB1 | 34 | HT+TELE+BRACHY | 60 | Alive |
R434 | ACC | IB1 | 34 | HT+TELE+BRACHY | 61 | Alive |
R443 | SCC | IB1 | 34 | HT+TELE+BRACHY | 61 | Alive |
R258 | SCC | IB1 | 36 | HT+TELE+BRACHY | 68 | Alive |
R335 | ACC | IB1 | 37 | HT+TELE+BRACHY+CHEMO | 65 | Alive |
R183 | SCC | IB1 | 64 | TELE+BRACHY | 61 | Alive |
R308 | ACC | IB1 | 45 | TELE+BRACHY | 61 | Alive |
R265 | SCC | IB1 | 46 | TELE+BRACHY | 67 | Alive |
R330 | SCC | IB1 | 72 | TELE+BRACHY | 54 | Alive |
R035 | SCC | IB2 | 48 | TELE+CHEMO+HT | 73 | Alive |
R221 | SCC | IB2 | 41 | TELE+BRACHY+CHEMO | 33 | Death* |
R232 | SCC | IB2 | 45 | TELE+BRACHY+CHEMO | 33 | Death |
R409 | SCC | IB2 | 68 | TELE+BRACHY+CHEMO | 42 | Alive |
R339 | SCC | IB2 | 31 | TELE+BRACHY+CHEMO | 13 | Death |
R324 | SCC | IB2 | 28 | TELE+BRACHY+CHEMO | 14 | Death |
R359 | ACC | IB2 | 34 | TELE+BRACHY+CHEMO | 17 | Death |
R378 | SCC | IB2 | 42 | TELE+BRACHY+CHEMO | 56 | Alive |
R396 | ACC | IB2 | 53 | TELE+BRACHY+CHEMO | 7 | Unknown |
R312 | ACC | IB2 | 34 | TELE+BRACHY+CHEMO | 58 | Alive |
R482 | SCC | IB2 | 61 | TELE+BRACHY+CHEMO | 60 | Alive |
R284 | ACC | IB2 | 33 | TELE+BRACHY+CHEMO | 63 | Alive |
R412 | SCC | IB2 | 33 | TELE+BRACHY+CHEMO | 63 | Alive |
R336 | SCC | IB2 | 36 | TELE+BRACHY+CHEMO | 64 | Alive |
R255 | SCC | IIA | 45 | TELE+BRACHY+CHEMO | 42 | Death |
R052 | ACC | IIB | 54 | TELE+BRACHY+HT | 19 | Death |
R070 | SCC | IIB | 74 | TELE+BRACHY+CHEMO | 4 | Unknown |
R170 | SCC | IIB | 67 | TELE+CHEMO+HT | 82 | Alive |
R403 | SCC | IIB | 34 | TELE+BRACHY+CHEMO | 64 | Alive |
R015 | SCC | IIB | 42 | TELE+HT | 66 | Alive |
R268 | SCC | IIB | 34 | TELE+BRACHY+CHEMO | 58 | Alive |
R415 | ASCC | IIB | 55 | TELE+BRACHY+CHEMO | 59 | Alive |
R441 | ACC | IIB | 24 | TELE+BRACHY+CHEMO | 10 | Unknown |
R333 | SCC | IIB | 56 | TELE+BRACHY+CHEMO | 66 | Alive |
R315 | SCC | IIIB | 41 | TELE+BRACHY+CHEMO | 8 | Death |
R240 | SCC | IIIB | 31 | TELE+BRACHY+CHEMO | 11 | Death |
ACC, Adenocarcinoma. SCC, Squamous Cell Carcinoma. ASCC, Adenosquamous Cell Carcinoma.
HT, Radical Hysterectomy. Tele, teletherapy. Brachy, brachytherapy. Chemo, chemotherapy with Cisplatin.
Status alive was registered at the last follow up, death was caused by primary tumor of cervical cancer, except the case labeled with an asterisk, and unknown cases were lost during the follow up study. The cause of death of case labeled with an asterisk was unknown.